Explore evidence

50 yearsThe median age of the HIV-2 patients was 50 years.

Côte d'IvoireVIH/sidapublished 2020PloS oneeurope_pmcdocument of 13 observationsDOI 10.1371/journal.pone.0236642

24 %Among hospitalized HIV-positive adults in West Africa, 24% discovered their HIV infection during the hospitalization.

Côte d'IvoireVIH/sidaobserved 2010published 2014Journal of the International AIDS Societyeurope_pmcdocument of 22 observationsDOI 10.7448/ias.17.1.18797

6,900 net_DALYs_per_yearThe resistance test policy led to 6900 fewer net DALYs per year compared with the switch policy.

Côte d'IvoireVIH/sidapublished 2025The lancet. HIVeurope_pmcdocument of 6 observations

5.4 log10_copies_per_mlThe median baseline HIV-1 RNA was 5.4 log10 copies/ml.

Côte d'IvoireVIH/sidapublished 2023AIDS (London, England)europe_pmcdocument of 6 observations

6.1 %HIV incidence among female sex workers who had 7 clients or more on the last day of work in Côte d'Ivoire was 6.1%.

Côte d'IvoireVIH/sidaobserved 2016-2017published 2022PloS oneeurope_pmcdocument of 10 observationsDOI 10.1371/journal.pone.0271988

No external and visible congenital malformation was observed in HIV-infected women exposed to nevirapine during pregnancy.

Côte d'IvoireVIH/sidaobserved 2003–2009published 2011Journal of acquired immune deficiency syndromes (1999)europe_pmcdocument of 9 observationsDOI 10.1097/qai.0b013e3181ff04e6

12 %At month 12 after ART initiation, 12% of patients in active follow-up had virus resistant to at least one antiretroviral drug.

Côte d'IvoireVIH/sidapublished 2013Journal of acquired immune deficiency syndromes (1999)europe_pmcdocument of 11 observations

462 per_mm3At baseline, the median CD4 count was 462/mm³ [IQR 368–571] in HIV-infected adults in the Temprano trial.

Côte d'IvoireVIH/sidapublished 2020EBioMedicineeurope_pmcdocument of 7 observations

63 %Among hospitalized HIV-positive adults in West Africa who died, the underlying cause of death was AIDS in 63% of cases.

Côte d'IvoireVIH/sidaobserved 2010published 2014Journal of the International AIDS Societyeurope_pmcdocument of 22 observationsDOI 10.7448/ias.17.1.18797

64.9 %The 60-month survival rate among ART-experienced HIV-2 patients with drug-resistant viruses was 64.9%.

Côte d'IvoireVIH/sidapublished 2020PloS oneeurope_pmcdocument of 13 observationsDOI 10.1371/journal.pone.0236642

11 %HIV prevalence among first-time female blood donors in Abidjan decreased from 11.0% in 1992–1994 to 2.0% in 2010–2012.

Côte d'IvoireVIH/sidaobserved 1992–1994published 2018Open forum infectious diseaseseurope_pmcdocument of 12 observations

3,016 copies/mlMedian plasma HIV-2 RNA among patients with viral load more than 50 copies/ml was 3016 copies/ml.

Côte d'IvoireVIH/sidapublished 2014AIDS (London, England)europe_pmcdocument of 9 observations

48 %In the West and Central African region, 48% of people living with HIV are aware of their HIV status.

Côte d'IvoireVIH/sidapublished 2020International journal of infectious diseases : IJID : official publication of the Internateurope_pmcdocument of 3 observations

69 %The majority of patients (69%) were under antiretroviral treatment.

Côte d'IvoireVIH/sidaobserved January 2005-July 2015published 2018The Pan African medical journaleurope_pmcdocument of 9 observations

54 %At month 24 after ART initiation, 54% of patients with detectable viral loads had resistant virus.

Côte d'IvoireVIH/sidapublished 2013Journal of acquired immune deficiency syndromes (1999)europe_pmcdocument of 11 observations

93 %A protease inhibitor was included in the antiretroviral chemoprophylaxis regimen in 93% of the cases.

Côte d'IvoireVIH/sidaobserved 2000-2007published 2010Medecine et maladies infectieuseseurope_pmcdocument of 13 observations

6.7 %Among 344 HIV-infected pregnant women who conceived on antiretroviral therapy, the overall proportion of stillborn was 6.7%.

Côte d'IvoireVIH/sidaobserved 2003–2009published 2011Journal of acquired immune deficiency syndromes (1999)europe_pmcdocument of 9 observationsDOI 10.1097/qai.0b013e3181ff04e6

35.3 %Thirty months after ART initiation, patients in the deferred group had a higher rate of virological failure (35.3% versus 29.9%).

Côte d'IvoireVIH/sidapublished 2021The Journal of antimicrobial chemotherapyeurope_pmcdocument of 8 observations

50 copies/mm3Virologic failure was defined as viral load > 50 copies/mm³.

Côte d'IvoireVIH/sidapublished 2025PloS oneeurope_pmcdocument of 12 observations

5.2 yearsThe interquartile range of follow-up duration was 5.2–6.3 years.

Côte d'IvoireVIH/sidapublished 2022HIV medicineeurope_pmcdocument of 6 observations

1.31 hazard_ratioPatients aged 50–59 years had an increased risk of death in the first 36 months on ART with an adjusted hazard ratio of 1.31.

Côte d'IvoireVIH/sidapublished 2018HIV/AIDS (Auckland, N.Z.)europe_pmcdocument of 7 observations

6.5 %Two (6.5%) HIV-2 patients switched to a PI-based regimen.

Côte d'IvoireVIH/sidapublished 2020PloS oneeurope_pmcdocument of 13 observationsDOI 10.1371/journal.pone.0236642

3.7 yearsMean time on failed first-line antiretroviral therapy was 3.7 years for the standard of care.

Côte d'IvoireVIH/sidapublished 2016Clinical infectious diseases : an official publication of the Infectious Diseases Society europe_pmcdocument of 5 observations

2.09 hazard_ratioIn multivariate Cox regression analysis, HIV-1 DNA levels ≥3 log10 copies/million PBMC were strongly associated with mortality (adjusted hazard ratio = 2.09, 95% CI 1.24–3.52, p = 0.005).

Côte d'IvoireVIH/sidapublished 2020EBioMedicineeurope_pmcdocument of 7 observations

0.61 hazard_ratio6 months of isoniazid preventive therapy reduced all-cause mortality with a hazard ratio of 0.61 (95% CI 0.39 to 0.94) after adjustment for ART strategy, baseline CD4 cell count, and other key characteristics in HIV-infected adults in Côte d'Ivoire.

Côte d'IvoireVIH/sidapublished 2017The Lancet. Global healtheurope_pmcdocument of 6 observations